



VEGF - how many types of VEGF are there

In humans, the **VEGF** family has five main mammalian members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PIGF). [\[1\]](#) [\[2\]](#) [\[3\]](#) [\[4\]](#) [\[5\]](#)

Core VEGF family members

- VEGF-A (often just called “VEGF”; multiple splice isoforms such as VEGF121, VEGF165, VEGF189, etc.). [\[3\]](#) [\[4\]](#) [\[1\]](#)
- VEGF-B. [\[2\]](#) [\[1\]](#) [\[3\]](#)
- VEGF-C. [\[1\]](#) [\[2\]](#) [\[3\]](#)
- VEGF-D. [\[2\]](#) [\[3\]](#) [\[1\]](#)
- Placental growth factor (PIGF). [\[5\]](#) [\[3\]](#) [\[1\]](#) [\[2\]](#)

These five come from distinct genes in mammalian genomes and are usually what people mean by “types of VEGF.” [\[3\]](#) [\[1\]](#) [\[2\]](#)

Additional non-mammalian VEGF-like factors

- Viral VEGF-like proteins (grouped as VEGF-E). [\[6\]](#) [\[1\]](#) [\[2\]](#)
- Snake venom VEGF-like proteins (grouped as VEGF-F). [\[7\]](#) [\[6\]](#) [\[1\]](#) [\[2\]](#)

If your question is about VEGF-A isoforms (e.g., VEGF121, 145, 165, 183, 189, 206), those are splice variants of the VEGF-A gene rather than separate VEGF family types. [\[8\]](#) [\[4\]](#) [\[7\]](#) [\[1\]](#) [\[3\]](#)

✱

What are the specific functions of VEGF-A VEGF-B VEGF-C VEGF-D and PIGF

VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PIGF each regulate different aspects of blood and lymphatic vessel biology and, in some cases, inflammation and disease-related angiogenesis. [\[14\]](#) [\[15\]](#) [\[16\]](#) [\[17\]](#) [\[18\]](#)

VEGF-A

- Major driver of angiogenesis: stimulates endothelial cell proliferation, migration, survival, and tube formation, promoting new blood vessel growth in development, wound healing, and tumors. [\[15\]](#) [\[19\]](#) [\[20\]](#) [\[18\]](#) [\[14\]](#)

- Increases vascular permeability and vasodilation, and can act as a chemoattractant for inflammatory cells; also shows neurotrophic and neuroprotective effects in the nervous system. [\[21\]](#) [\[20\]](#) [\[14\]](#) [\[15\]](#)

VEGF-B

- Binds mainly to VEGFR1 and is involved in embryonic angiogenesis, particularly in the heart and myocardial tissue. [\[16\]](#) [\[14\]](#) [\[15\]](#) [\[21\]](#)
- Implicated in metabolic and cardiac protection rather than strong vessel sprouting; contributes to survival of endothelial and other cells under stress. [\[22\]](#) [\[14\]](#) [\[16\]](#) [\[21\]](#)

VEGF-C

- Primary regulator of lymphangiogenesis: drives growth, proliferation, and migration of lymphatic endothelial cells via VEGFR3, crucial for development of the lymphatic system. [\[23\]](#) [\[14\]](#) [\[15\]](#) [\[16\]](#)
- When fully processed, can also bind VEGFR2 and contribute to angiogenesis and vascular remodeling, especially in cancer and tissue repair. [\[14\]](#) [\[23\]](#) [\[16\]](#) [\[22\]](#)

VEGF-D

- Works similarly to VEGF-C in promoting lymphangiogenesis through VEGFR3, particularly in tissues such as lung, heart, and intestine. [\[15\]](#) [\[23\]](#) [\[16\]](#) [\[22\]](#) [\[14\]](#)
- Can also activate VEGFR2 (especially after proteolytic processing), contributing to both angiogenesis and lymphatic vessel remodeling, including in tumor metastasis and peribronchial lymphatic development. [\[23\]](#) [\[16\]](#) [\[22\]](#) [\[14\]](#) [\[15\]](#)

PlGF (Placental Growth Factor)

- Binds selectively to VEGFR1 and is important for vasculogenesis and pathological angiogenesis in ischemia, inflammation, wound healing, and cancer. [\[17\]](#) [\[14\]](#) [\[15\]](#)
- Enhances angiogenesis mainly under disease conditions by amplifying VEGF-A signaling (displacing VEGF-A from VEGFR1 to VEGFR2) and by recruiting and activating inflammatory and myeloid cells in affected tissues. [\[17\]](#) [\[14\]](#)

*
*

Which types support cancer tumor growth

All five main VEGF family members can contribute to cancer, but **VEGF-A** and the lymphangiogenic factors **VEGF-C** and **VEGF-D** are the primary drivers of tumor growth and metastasis, with **PlGF** and **VEGF-B** playing more context-dependent, supportive roles. [\[24\]](#) [\[25\]](#) [\[26\]](#) [\[27\]](#) [\[28\]](#) [\[29\]](#) [\[30\]](#)

Summary by VEGF type

- **VEGF-A:** Central pro-angiogenic factor in most solid tumors; promotes new blood vessel growth, supports tumor survival, and enhances metastatic spread via both paracrine and autocrine signaling in cancer cells. [\[25\]](#) [\[31\]](#) [\[32\]](#) [\[27\]](#) [\[28\]](#) [\[24\]](#)
- **VEGF-C:** Strongly promotes tumor lymphangiogenesis and lymph node metastasis; high tumor VEGF-C expression is linked to increased spread to regional and distant lymph nodes and sometimes lungs. [\[26\]](#) [\[33\]](#) [\[29\]](#) [\[34\]](#)
- **VEGF-D:** Similar to VEGF-C, supports tumor-associated lymphatic vessel growth and metastasis through lymphatic routes; blocking VEGF-C/-D-VEGFR3 signaling reduces lymphatic and lung metastases in models. [\[29\]](#) [\[26\]](#)
- **PIGF:** Can promote tumor angiogenesis, growth, and resistance to anti-VEGF therapies by acting via VEGFR1 and by recruiting pro-angiogenic myeloid cells; however, in some settings PIGF-VEGF heterodimers can dampen VEGF-A-driven angiogenesis, so its effect is context dependent. [\[35\]](#) [\[36\]](#) [\[30\]](#)
- **VEGF-B:** Much weaker driver of classic angiogenesis; may support tumor cell survival and metabolism in certain cancers, but is not usually a primary target like VEGF-A, VEGF-C, or VEGF-D. [\[27\]](#) [\[37\]](#) [\[25\]](#)

*
**

How is VEGF produced

VEGF is a secreted protein growth factor that cells synthesize and release in response to signals such as low oxygen and various cytokines and growth factors. [\[39\]](#) [\[40\]](#) [\[41\]](#)

Cells that make VEGF

- Many cell types can produce VEGF, including epithelial cells, fibroblasts, smooth muscle cells, immune cells, and tumor cells; endothelial cells usually respond to VEGF rather than being the main source. [\[40\]](#) [\[41\]](#) [\[42\]](#) [\[43\]](#)
- Production happens after the VEGF gene is transcribed into mRNA and translated into a precursor protein that is then processed and secreted. [\[44\]](#) [\[45\]](#) [\[40\]](#)

Main triggers for VEGF production

- **Hypoxia (low oxygen):** Hypoxia-inducible factors (HIF-1 α , HIF-2 α) become stabilized, move into the nucleus, bind hypoxia-response elements in the VEGF promoter, and upregulate VEGF transcription. [\[45\]](#) [\[41\]](#) [\[39\]](#) [\[40\]](#)
- **Other stimuli:** Inflammatory cytokines, mechanical stress, hormones, and oncogenic signaling pathways can also increase VEGF expression via additional transcriptional regulators (for example, PGC-1 α /ERR α in muscle). [\[41\]](#) [\[43\]](#) [\[40\]](#) [\[45\]](#)

Processing and secretion

- VEGF is synthesized as a prepro-peptide in the endoplasmic reticulum, processed in the Golgi, and secreted as a dimeric glycoprotein. [\[40\]](#) [\[45\]](#) [\[41\]](#)
- Alternative splicing produces different VEGF-A isoforms; those containing certain exons bind heparan sulfate and extracellular matrix, so some VEGF remains locally sequestered while more diffusible isoforms spread farther from the producing cell. [\[45\]](#) [\[40\]](#)

If you like, I can next break down VEGF-A production specifically versus VEGF-C/D, which require extra proteolytic processing to become fully active.



BPC 157 and TB500 both support VEGF, do they increase VEGF production and use if there is no demand from the cell

Evidence in cells and animal models suggests BPC-157 and TB-500 can upregulate VEGF signaling in injured or stressed tissue, but it is not well proven that they chronically drive high VEGF production in completely normal, “no-demand” conditions in humans. [\[49\]](#) [\[50\]](#) [\[51\]](#) [\[52\]](#) [\[53\]](#) [\[54\]](#) [\[55\]](#)

What BPC-157 seems to do

- BPC-157 promotes angiogenesis and healing mainly by increasing VEGFR2 expression and activating the VEGFR2–Akt–eNOS pathway, often without significantly raising VEGF-A levels in some endothelial models. [\[50\]](#) [\[51\]](#) [\[56\]](#)
- Several studies show VEGF and/or VEGFR2 upregulation in ischemic or injured tissue, with improved blood flow and vessel formation, i.e., in clear “demand” contexts such as hind-limb ischemia or ulcers. [\[57\]](#) [\[58\]](#) [\[50\]](#)
- Newer reviews emphasize that BPC-157 tends to normalize or limit pathological angiogenesis (for example, preventing corneal neovascularization) rather than causing unchecked vessel growth, which argues against a simple “always up” VEGF effect. [\[59\]](#) [\[53\]](#)

What TB-500 (thymosin β 4) seems to do

- Thymosin β 4 (the peptide that TB-500 is based on) can increase VEGF expression and VEGF-dependent angiogenesis in models of heart injury, hair follicle growth, and endothelial progenitor cell function. [\[52\]](#) [\[54\]](#) [\[55\]](#)
- These studies typically use injury, ischemia, or specific growth contexts (e.g., infarcted heart, damaged tissues), again implying that VEGF upregulation is most pronounced when there is biological “demand” for repair. [\[54\]](#) [\[55\]](#) [\[52\]](#)

The key unknown (your actual question)

- There are **no robust human data** showing what chronic BPC-157 or TB-500 use does to VEGF in completely healthy tissues with no injury, and existing animal/cell work is designed around damage or stress models. [\[53\]](#) [\[60\]](#) [\[49\]](#) [\[59\]](#)
- Mechanistically, both peptides can sensitize or enhance VEGF pathways, so in theory they could modestly raise baseline VEGF signaling, but whether that happens meaningfully in normal tissue—and for how long—is not established. [\[56\]](#) [\[49\]](#) [\[50\]](#) [\[52\]](#) [\[54\]](#)

Practical takeaway

- Current evidence supports “context-dependent support” of VEGF signaling (especially during injury or ischemia), not a clearly documented, sustained VEGF overproduction in the absence of cellular demand. [\[49\]](#) [\[50\]](#) [\[52\]](#) [\[53\]](#)
- Because VEGF is tightly regulated and involved in cancer biology, any off-label use of pro-angiogenic peptides should be approached cautiously, especially in people with a history or high risk of malignancy or proliferative eye disease. [\[61\]](#) [\[62\]](#) [\[63\]](#)



Is there a safety risk with BPC and TB500, if yes how and why and what would the risk level be

Yes, there are meaningful safety uncertainties and some theoretical risks with both BPC-157 and TB-500, mainly because they are pro-repair, pro-angiogenic peptides that have not been through full human drug development. [\[67\]](#) [\[68\]](#) [\[69\]](#) [\[70\]](#) [\[71\]](#) [\[72\]](#)

Big-picture risk level

- Neither BPC-157 nor TB-500 is approved by the FDA or EMA; they are sold in an unregulated “research chemical” market, so purity, dose, and contaminants are uncertain. [\[68\]](#) [\[70\]](#) [\[73\]](#) [\[71\]](#)
- Preclinical data for BPC-157 and thymosin β 4 (TB-500 analog) generally show low acute toxicity, but human data are extremely limited, so true long-term and rare risks are unknown. [\[74\]](#) [\[69\]](#) [\[75\]](#) [\[72\]](#) [\[67\]](#)

Specific concerns with BPC-157

- BPC-157 activates multiple growth and migration pathways (e.g., FAK–paxillin, VEGF/VEGFR2–Akt–eNOS), which theoretically could aid tumor growth or metastasis if malignant cells are present. [\[76\]](#) [\[77\]](#) [\[78\]](#) [\[79\]](#) [\[67\]](#)
- Reviews highlight conflicting cancer signals: some cell/animal data hint at anti-tumor effects, others raise concern about potential support of tumor progression; overall, the cancer-risk question is unresolved. [\[77\]](#) [\[69\]](#) [\[80\]](#) [\[67\]](#)
- First small human data suggest short-term tolerability, but this is not enough to judge long-term safety, carcinogenicity, or effects in people with prior cancer or strong risk factors.

[69] [73] [71] [74]

Specific concerns with TB-500 (thymosin β 4)

- TB-500 is also not approved; preparations are often misbranded, and significant batch-to-batch variability has been reported. [70] [75] [68]
- Documented adverse effects include severe hypersensitivity and anaphylaxis, cardiovascular collapse, pulmonary edema, and a range of allergic-type and systemic reactions, especially with repeated injections. [70]
- Mechanistically, thymosin β 4 can influence angiogenesis, cell migration, and fibroblast activation, so experts caution about theoretical risks of abnormal fibrosis or effects on tumor biology, particularly in people with active or recent cancer. [72] [81] [68]

Practical risk framing

- For a healthy person with no cancer history, the *known* short-term toxicity signal is low but the *unknowns* (long-term cancer risk, vascular or fibrosis effects, autoimmunity) are large, because proper Phase II/III trials do not exist. [75] [71] [67] [68] [69] [72]
- For anyone with current cancer, prior cancer, strong family history, proliferative eye disease, or clotting/vascular problems, most cautious clinicians recommend avoiding pro-angiogenic experimental peptides like BPC-157 and TB-500 outside of a controlled trial. [82] [83] [84] [77] [69] [72]

If you tell me your medical context (injury type, prior cancer, meds), I can help you frame the risk more specifically for your situation, to discuss with your physician.



Is VEGF only produced on demand

VEGF is produced both **basally** and **on demand**; most tissues have a constant low-level output, which can then be strongly increased when there is a trigger such as hypoxia, inflammation, or growth signals. [88] [89] [90] [91] [92]

Basal (constitutive) VEGF

- Many adult organs (lung, kidney, heart, adrenal gland, liver, etc.) show VEGF mRNA and protein even when there is no active angiogenesis, helping maintain existing vessels and baseline permeability. [90] [91] [92] [88]
- Certain cells (for example, retinal pigment epithelium, megakaryocytes/platelets) secrete VEGF constitutively under normal conditions, regulated by transcription factors like NF- κ B and MAPK pathways. [93] [94] [95] [96]

Inducible (on-demand) VEGF

- Hypoxia is a major on-demand trigger: stabilization of HIF-1 α under low oxygen markedly increases VEGF transcription and secretion to drive new vessel growth and improve oxygen delivery. [\[89\]](#) [\[97\]](#) [\[92\]](#)
- Additional “demand” signals include inflammation, mechanical stress, and oncogenic signaling, which can further upregulate VEGF beyond the basal level in specific tissues or disease states. [\[92\]](#) [\[98\]](#) [\[90\]](#)

So VEGF is not only produced when there is obvious damage; there is a baseline production needed for normal vascular and tissue homeostasis, which is then layered with strong inducible surges when demand increases. [\[91\]](#) [\[88\]](#) [\[90\]](#) [\[92\]](#)



BPC 157 and Thymosin Beta 4, do they increase basal levels or VEGF

Evidence suggests BPC-157 and thymosin beta-4 mainly **enhance VEGF signaling and injury-induced VEGF responses**, but it is not clearly shown that they significantly raise *basal* VEGF levels in completely normal tissues. [\[103\]](#) [\[104\]](#) [\[105\]](#) [\[106\]](#) [\[107\]](#)

BPC-157

- In endothelial cell systems, BPC-157 activates the VEGFR2–Akt–eNOS pathway and increases VEGFR2 expression, enhancing VEGF signaling even without adding extra VEGF, which can make cells more responsive to existing VEGF. [\[108\]](#) [\[105\]](#) [\[103\]](#)
- In injury models (crushed muscle, transected tendon, ischemic limb, gastric lesions), BPC-157 is associated with higher VEGF expression and stronger VEGF staining in healing tissue, indicating it amplifies the injury-driven VEGF response. [\[109\]](#) [\[110\]](#) [\[105\]](#) [\[111\]](#)
- One muscle-healing study noted no direct angiogenic effect in simple cell culture but “adequately modulated” VEGF and angiogenesis *in vivo*, suggesting its effect is tightly linked to a damage context rather than a big baseline push. [\[110\]](#) [\[111\]](#)

Thymosin beta-4 (TB-4 / TB-500)

- Thymosin beta-4 can induce VEGF expression via stabilizing HIF-1 α and maintaining nitric oxide production; this has been shown in hypoxic or cancer cell models and ischemic/injured tissues. [\[104\]](#) [\[106\]](#) [\[112\]](#)
- VEGF upregulation by thymosin beta-4 is most clearly demonstrated under hypoxia or stress (e.g., ischemic myocardium, hypoxic tumor cells), where it boosts VEGF mRNA and protein as part of an adaptive response. [\[106\]](#) [\[112\]](#) [\[104\]](#)

What is *not* known

- There are no good human data, and very limited animal data, specifically measuring VEGF in multiple *normal*, uninjured tissues before and after chronic BPC-157 or TB-500 exposure, so we cannot say confidently that basal VEGF stays unchanged. [\[105\]](#) [\[113\]](#) [\[107\]](#)
- The best current interpretation is that both peptides are **context-dependent pro-angiogenic modulators**—they can upregulate VEGF expression and signaling where repair or hypoxia signals are present, but chronic elevation of systemic basal VEGF has not been clearly demonstrated. [\[107\]](#) [\[103\]](#) [\[104\]](#) [\[105\]](#)

~

Differences in VEGF mechanisms between BPC 157 and TB4

BPC-157 and thymosin beta-4 both intersect with VEGF and angiogenesis, but they act at **different points in the pathway**: BPC-157 mainly **sensitizes VEGF signaling at the receptor level**, whereas thymosin beta-4 more clearly **drives VEGF production upstream via HIF-1 α /NO**, especially under hypoxia. [\[118\]](#) [\[119\]](#) [\[120\]](#) [\[121\]](#) [\[122\]](#) [\[123\]](#) [\[124\]](#) [\[125\]](#)

BPC-157: receptor-side VEGF modulation

- Directly upregulates VEGFR2 (KDR/Flk-1) expression at mRNA and protein level in endothelial cells, increasing the number of receptors available for VEGF binding. [\[119\]](#) [\[126\]](#) [\[127\]](#) [\[124\]](#) [\[118\]](#)
- Promotes VEGFR2 internalization and phosphorylation and activates downstream Akt and eNOS, boosting nitric oxide production, endothelial migration, and tube formation, even without increasing VEGF-A itself in some in-vitro models. [\[128\]](#) [\[126\]](#) [\[127\]](#) [\[118\]](#) [\[119\]](#)
- In vivo injury models, its pro-angiogenic and healing effects correlate with higher VEGF staining and more robust neovascularization, but mechanistically it is often described as a **VEGFR2–Akt–eNOS pathway activator** rather than a primary VEGF gene inducer. [\[124\]](#) [\[129\]](#) [\[130\]](#) [\[118\]](#)

Thymosin beta-4 (TB-4/TB-500): upstream VEGF induction

- Thymosin beta-4 is an actin-sequestering protein that, under hypoxia or NO signaling, helps stabilize HIF-1 α , a key transcription factor that directly drives VEGF gene expression. [\[120\]](#) [\[121\]](#) [\[123\]](#) [\[125\]](#)
- In cancer and hypoxia models, T β 4 increases VEGF mRNA and protein by maintaining nitric-oxide synthase activity and NO production; blocking NO or knocking down T β 4 reduces HIF-1 α and VEGF levels. [\[121\]](#) [\[123\]](#) [\[125\]](#) [\[120\]](#)
- Functionally, this positions thymosin beta-4 as a **regulator of VEGF expression and hypoxia-responsive angiogenesis**, contributing to vessel growth, cell migration, and tissue remodeling, especially after ischemic or structural injury. [\[125\]](#) [\[131\]](#) [\[120\]](#) [\[124\]](#)

Mechanistic contrast in one line

- **BPC-157:** Mostly “turns up the volume” on VEGF signaling by increasing VEGFR2 density and activating VEGFR2-Akt-eNOS, with context-dependent VEGF changes.^{[126] [129] [118] [119] [124]}
- **Thymosin beta-4:** More clearly increases VEGF production by stabilizing HIF-1 α and sustaining NO/NOS activity under stress, acting higher up in the hypoxia-VEGF axis.^{[123] [120] [121] [125]}

~

What are the major drivers of cancer related to age

The main age-related drivers of cancer are the gradual buildup of DNA and epigenetic damage, declining genome maintenance, and an older tissue environment (immune and inflammatory) that makes it easier for mutated cells to survive and expand.^{[137] [138] [139] [140] [141] [142] [143]}

1. Accumulated DNA damage and genomic instability

- With age, cells collect mutations from replication errors, oxidative stress, UV, toxins, and chronic inflammation, leading to **genomic instability**, a core “enabling hallmark” of cancer.^{[138] [139] [140] [143] [137]}
- When enough mutations hit growth-control genes (oncogenes, tumor suppressors) in a cell that can still divide, it can clonally expand into a pre-cancer and then cancer.^{[139] [144] [141] [142] [137]}

2. Telomere shortening and repair failure

- Telomeres normally shorten with each cell division; in aging, critically short telomeres drive cellular senescence or crisis, increasing DNA breaks and chromosomal instability.^{[145] [140] [146] [139]}
- Early in carcinogenesis, telomere erosion promotes genome rearrangements, and later cancers often reactivate telomerase to maintain longer telomeres and keep dividing.^{[140] [139]}

3. Epigenetic and metabolic drift

- Aging tissues show **epigenetic alterations** (DNA methylation changes, histone modifications) that can silence tumor suppressors or activate proto-oncogenes without changing the DNA sequence.^{[146] [145] [138] [139]}
- Age-related shifts in nutrient sensing and mitochondrial metabolism can favor cancer traits like altered energy use and resistance to cell death.^{[147] [145] [139] [140]}

4. Stem cell aging and clonal expansion

- Over time, tissue stem and progenitor cells accumulate mutations and epigenetic changes, leading to mutant clones that can dominate (clonal hematopoiesis, intestinal clones, etc.). [\[144\]](#) [\[141\]](#) [\[137\]](#) [\[138\]](#)
- Some of these clones carry driver mutations and are at higher risk of progressing to leukemia or solid tumors as additional hits accumulate. [\[141\]](#) [\[138\]](#) [\[144\]](#)

5. Immunosenescence and chronic inflammation

- The aging immune system loses surveillance capacity (**immunosenescence**), so it becomes less effective at detecting and clearing emerging cancer cells. [\[148\]](#) [\[139\]](#) [\[141\]](#)
- Older individuals often have low-grade chronic inflammation (“inflammaging”), which increases reactive oxygen species and growth factors in tissues, fostering DNA damage and a tumor-promoting microenvironment. [\[142\]](#) [\[145\]](#) [\[139\]](#) [\[148\]](#) [\[140\]](#)

If you tell me your age range and main concerns (family history, lifestyle, hormone use, etc.), I can narrow this to the most relevant modifiable factors for you.

*~

If one were to address these 5 drivers list them in order of importance and best way to address and improve each

Addressing all five helps, but a practical order is:

1. DNA/genome protection
2. Chronic inflammation
3. Metabolism/epigenetics
4. Immune aging
5. Stem-cell/clonal issues. [\[152\]](#) [\[153\]](#) [\[154\]](#) [\[155\]](#) [\[156\]](#) [\[157\]](#) [\[158\]](#) [\[159\]](#)

1. DNA damage and genomic instability (highest priority)

Best levers (daily habits with largest evidence base):

- Do not smoke; avoid secondhand smoke and vaping aerosols. [\[160\]](#) [\[155\]](#) [\[152\]](#)
- UV protection: regular sunscreen, hats, avoiding burns and tanning beds. [\[161\]](#) [\[152\]](#)
- Keep alcohol low (ideally ≤ 1 drink/day or less, with some guidelines advocating near-zero for cancer risk). [\[162\]](#) [\[163\]](#)
- Maintain healthy weight and regular exercise (150–300 minutes/week moderate plus some resistance work). [\[163\]](#) [\[162\]](#)

- Emphasize a plant-forward diet (vegetables, fruit, whole grains, legumes, nuts) and limit ultra-processed foods; this reduces oxidative stress and improves DNA-damage markers. [\[164\]](#) [\[165\]](#) [\[152\]](#) [\[163\]](#)
- Sleep 7–9 hours and manage stress (meditation, yoga, CBT); these have been linked to lower DNA damage markers and better telomere maintenance. [\[162\]](#) [\[152\]](#)

2. Chronic inflammation (“inflammaging”)

Best levers:

- Follow an anti-inflammatory pattern such as Mediterranean-style eating: olive oil, fish, legumes, whole grains, high produce, low processed meat and refined carbs. [\[153\]](#) [\[154\]](#) [\[165\]](#) [\[163\]](#) [\[164\]](#)
- Keep visceral fat down (waist circumference) with diet and exercise; central obesity is a strong driver of inflammatory cytokines. [\[154\]](#) [\[163\]](#)
- Treat gum disease, sleep apnea, and chronic infections, which can all sustain inflammation. [\[166\]](#) [\[153\]](#)
- Use NSAIDs (e.g., aspirin) only under medical advice; they can lower risk of some cancers but carry bleeding and other risks. [\[154\]](#)

3. Epigenetic and metabolic drift

Best levers:

- Avoid chronic over-nutrition; modest caloric moderation and avoiding large glucose spikes improve epigenetic and metabolic markers linked to cancer. [\[167\]](#) [\[168\]](#) [\[169\]](#)
- Prioritize fiber and polyphenols (berries, greens, herbs, tea, coffee) and healthy fats (olive oil, nuts, omega-3s), which modulate DNA methylation and mitochondrial function. [\[165\]](#) [\[163\]](#) [\[153\]](#) [\[167\]](#)
- Maintain good metabolic health: normal blood pressure, lipids, and insulin sensitivity (through weight control, activity, and possibly medications like metformin if indicated by your doctor). [\[168\]](#) [\[167\]](#)

4. Immunosenescence (aging immune system)

Best levers:

- Stay current on vaccines (flu, COVID-19, pneumococcal, shingles, etc.), which reduces chronic immune activation and opportunistic infections. [\[170\]](#) [\[153\]](#) [\[166\]](#)
- Regular aerobic and resistance exercise; in older adults this is linked to more diverse T-cell repertoires and lower inflammatory markers. [\[153\]](#) [\[170\]](#) [\[166\]](#)
- Mediterranean-style, high-fiber diet to support microbiome health and gut barrier integrity, which improves immune aging and reduces systemic inflammation. [\[170\]](#) [\[166\]](#) [\[153\]](#)
- Good sleep and stress management (yoga, mindfulness, social connection) to lower stress-hormone-driven immune dysfunction. [\[162\]](#) [\[153\]](#) [\[170\]](#)

5. Stem-cell aging and clonal expansion

You cannot fully “fix” this, but you can reduce additional hits and detect problems early.

- All the above (DNA protection, anti-inflammatory diet, exercise, metabolic health) reduce the rate at which stem cells accumulate damaging mutations. [\[155\]](#) [\[156\]](#) [\[157\]](#) [\[159\]](#) [\[171\]](#)
- Avoid unnecessary high-dose radiation and cytotoxic exposures (imaging only when clinically justified, careful workplace protection). [\[152\]](#) [\[160\]](#) [\[155\]](#)
- Keep up with age-appropriate cancer screening (colonoscopy, stool tests, breast imaging, prostate discussion, skin checks, etc.) so clonal lesions are caught early. [\[159\]](#) [\[172\]](#)

If you tell me your age, sex, and a bit about your lifestyle (smoking, weight, exercise, family history), I can turn this into a short, prioritized action list geared to you specifically.

~

how important is the immune system in this process

The immune system is **central** to how aging turns into cancer risk; it is not a side factor but one of the main gatekeepers that decides whether mutated cells are eliminated, contained, or allowed to grow. [\[176\]](#) [\[177\]](#) [\[178\]](#) [\[179\]](#) [\[180\]](#) [\[181\]](#)

How important is it, conceptually?

- Immune surveillance (mainly T cells, NK cells, and dendritic cells) constantly patrols tissues and can recognize and destroy emerging tumor cells; when this system is impaired, cancer incidence and progression increase. [\[182\]](#) [\[177\]](#) [\[183\]](#) [\[184\]](#) [\[176\]](#)
- Aging of the immune system (immunosenescence) is now considered a **major** contributor to age-related cancer, alongside DNA damage and tissue aging, because it allows more mutated clones to escape detection and shapes a tumor-friendly microenvironment. [\[179\]](#) [\[185\]](#) [\[180\]](#) [\[181\]](#) [\[186\]](#) [\[187\]](#)

Concrete evidence for its importance

- Immunosuppressed people (organ transplant recipients, HIV with low CD4 counts, chronic immunosuppressive drugs) have markedly higher rates of many cancers, especially virus-driven ones, demonstrating how crucial immune surveillance is. [\[177\]](#) [\[184\]](#) [\[176\]](#)
- Experimental models where key cytotoxic functions (e.g., perforin-1, IFN- γ pathways) are knocked out show more tumors and faster aging, indicating that failure of immunosurveillance accelerates both cancer and aging processes. [\[178\]](#) [\[180\]](#) [\[181\]](#)
- Reviews of immunosenescence describe age-related declines in T-cell production, NK function, and cytokine balance that collectively increase malignancy risk and worsen treatment responses in older adults. [\[185\]](#) [\[180\]](#) [\[181\]](#) [\[186\]](#) [\[179\]](#)

How to think about it relative to other drivers

- DNA damage creates potentially malignant cells; the **immune system decides** how many of those ever become clinical cancers, so it sits at the interface between “having mutations” and “getting cancer.” [\[180\]](#) [\[186\]](#) [\[187\]](#) [\[188\]](#) [\[189\]](#)
- Practically, that means that supporting immune fitness (exercise, vaccines, sleep, Mediterranean-style diet, weight control, avoiding unnecessary immunosuppression) is one of the highest-yield levers you have to influence age-related cancer risk, alongside DNA and inflammation control. [\[181\]](#) [\[190\]](#) [\[191\]](#) [\[192\]](#) [\[185\]](#)

If you want, I can outline a short immune-health checklist tailored to your age and lifestyle that aligns with cancer-prevention guidelines.



What blood markers would indicate immune system state and how to interpret those markers

The immune system’s state shows up indirectly on routine labs and more directly on specialized immune panels. [\[197\]](#) [\[198\]](#) [\[199\]](#) [\[200\]](#) [\[201\]](#)

1. Basic, widely available markers

These are what most people can get from a standard lab:

- **CBC with differential (WBC, lymphocytes, neutrophils, etc.)**
 - WBC: high can mean acute infection or inflammation; very low can indicate bone marrow or immune suppression. [\[198\]](#) [\[202\]](#) [\[197\]](#)
 - Absolute lymphocyte count (ALC): normal adult range is roughly 1,000–4,800/μL; persistent lymphopenia (ALC <1,000) suggests weakened adaptive immunity or immunosuppressive drugs/infection. [\[203\]](#) [\[204\]](#) [\[205\]](#)
 - Neutrophils, monocytes, eosinophils, basophils: shifts can reflect acute infection, allergy, chronic inflammation, or marrow disease. [\[205\]](#) [\[197\]](#)
- **CRP and ESR (general inflammation)**
 - C-reactive protein (CRP): high-sensitivity CRP persistently above about 2–3 mg/L (outside acute infection) suggests chronic low-grade inflammation, which is linked to higher cardiovascular and some cancer risks. [\[206\]](#) [\[207\]](#) [\[208\]](#)
 - ESR: nonspecific; chronically elevated ESR supports the presence of ongoing inflammation or chronic disease. [\[197\]](#)
- **Metabolic and liver markers (indirect)**
 - Poor metabolic health (high fasting glucose, high triglycerides, low HDL, fatty liver enzymes) often reflects systemic low-grade inflammation and altered immune signaling. [\[199\]](#) [\[207\]](#) [\[209\]](#)

2. Inflammation and “immune-activation” markers

More detailed but still available in many clinics:

- **IL-6, TNF- α , sometimes IL-1 β**
 - Elevated levels at baseline (not just during infection) indicate chronic immune activation and have been linked to higher risk of cancer incidence and death in population studies. [\[210\]](#) [\[201\]](#) [\[211\]](#) [\[206\]](#)
 - Interpretation: higher values = more systemic inflammation; the exact “cutoffs” vary by lab, so trends and relative elevation above reference are more important than a single number.
- **Fibrinogen, ferritin**
 - Both behave as acute-phase reactants; chronically high values often track with ongoing inflammatory burden. [\[199\]](#) [\[197\]](#)

3. Immune “cell profile” / lymphocyte phenotyping

These tests are more specialized and usually ordered by an immunologist or hematologist:

- **CD4, CD8 counts and CD4:CD8 ratio**
 - Normal CD4:CD8 ratio is often around 1.5–2; a ratio persistently <1 can indicate immune impairment or chronic immune activation, as seen in some infections and aging. [\[200\]](#) [\[199\]](#)
 - Low CD4 counts (with or without low CD8) suggest impaired T-cell-mediated immunity. [\[200\]](#)
- **NK cells and T-cell subsets (naive, memory, exhausted cells)**
 - Aging and immunosenescence are associated with fewer naive T cells, more terminally differentiated/exhausted T cells (often CD57+, KLRG1+, TIM-3+), and altered NK cell subsets. [\[212\]](#) [\[201\]](#) [\[213\]](#) [\[199\]](#)
 - Interpretation: a shift toward exhausted/late-stage T cells and reduced naive pools points to an “aged” immune profile, which correlates with higher frailty and cancer risk in studies. [\[213\]](#) [\[212\]](#) [\[199\]](#)

4. Putting it together: how to read your labs for immune state

In practical terms, a “healthier” immune profile tends to look like:

- CBC: WBC and differential within range, ALC in or near mid-normal, no chronic neutrophilia or unexplained lymphopenia. [\[203\]](#) [\[198\]](#) [\[197\]](#)
- Inflammation: hs-CRP in the low range (often <1 mg/L) outside of infections; IL-6 and TNF- α not chronically elevated if measured. [\[201\]](#) [\[207\]](#) [\[206\]](#)
- Phenotyping (if done): CD4:CD8 ratio not severely inverted, a reasonable pool of naive T cells, not dominated by highly exhausted/senescent (CD57+, TIM-3+, etc.) T cells. [\[212\]](#) [\[213\]](#) [\[199\]](#) [\[200\]](#)

Because “normal” varies with age and context, the best way to use these markers is as a **pattern plus trend** rather than single cutoffs, ideally interpreted with a clinician who knows your history.

If you share your age, sex, and any recent lab values (CBC, CRP, fasting glucose/lipids), I can walk through what they suggest about your immune/inflammatory state.



Optimal ranges for CD4 CD8 ratio in adults

For most healthy adults, a **CD4:CD8 ratio between about 1 and 3 is considered normal**, with many labs and studies centering around roughly 1.5–2.0. [\[215\]](#) [\[216\]](#) [\[217\]](#) [\[218\]](#) [\[219\]](#)

Typical “optimal” range

- Many references describe a normal CD4:CD8 ratio as **greater than 1.0**, often around **1.0–2.0 (up to ~3)** in immunologically healthy adults. [\[216\]](#) [\[217\]](#) [\[218\]](#) [\[219\]](#) [\[215\]](#)
- Population studies in healthy adults often find mean ratios around **1.4–1.7**, with 95% of people falling roughly between **0.4–3.0**, depending on lab and population. [\[217\]](#) [\[220\]](#) [\[215\]](#)

How to interpret values

- **>1.0 (about 1–3)**: Generally indicates a balanced T-cell compartment and is considered in the normal/healthy range if absolute CD4 and CD8 counts are also within reference limits. [\[218\]](#) [\[219\]](#) [\[215\]](#) [\[216\]](#) [\[217\]](#)
- **<1.0 (“inverted” ratio)**: Suggests relative CD4 loss and/or CD8 expansion, seen with chronic immune activation, immunosenescence, or conditions such as untreated HIV; it is associated with higher risk of immune dysfunction and age-related disease in several cohorts. [\[221\]](#) [\[222\]](#) [\[216\]](#)
- **Very high ratio (e.g., >3)**: Less common; can occur with very high CD4 counts or low CD8 counts and needs to be interpreted in context of symptoms and other labs, not as “better is always higher.” [\[215\]](#) [\[217\]](#) [\[218\]](#)

If you have your actual CD4, CD8, and ratio values (plus age), paste them and I can walk through what they likely mean for you.



How does age affect CD4 CD8 ratio

Age tends to **push the CD4:CD8 ratio down**, and a persistently low or “inverted” ratio in older adults is viewed as a marker of immune aging (immunosenescence), frailty, and higher comorbidity risk. [\[225\]](#) [\[226\]](#) [\[227\]](#) [\[228\]](#) [\[229\]](#)

Typical age-related pattern

- In younger healthy adults, the CD4:CD8 ratio is usually above 1 (often around 1.5–2), reflecting more CD4 helper T cells than CD8 cytotoxic T cells. [\[227\]](#) [\[230\]](#) [\[231\]](#)
- With aging, chronic antigen exposure (especially lifelong viruses like CMV) and thymic shrinkage lead to expansion of late-stage CD8 T cells and loss of naive CD4 T cells, so the ratio tends to **decline** and is more likely to fall below 1 in older people. [\[226\]](#) [\[228\]](#) [\[229\]](#) [\[227\]](#)

What a low ratio means in older adults

- An “inverted” ratio (CD4:CD8 <1) in elderly populations has been associated with more markers of oxidative stress, higher inflammatory markers, more comorbidities, and reduced physical function or independence. [\[228\]](#) [\[232\]](#) [\[229\]](#) [\[226\]](#)
- Studies suggest that a low ratio captures cumulative immune stress and senescence and can act as an integrative marker of **biological** rather than just chronological age, although it is not a perfect predictor of mortality by itself. [\[229\]](#) [\[233\]](#) [\[225\]](#) [\[226\]](#)

If you tell me your age and your actual CD4, CD8, and ratio, I can help you interpret whether your result fits what we'd expect for age or suggests extra immune stress.

✱

How does the thymic involution affect the immune system as we age

Thymic involution (the gradual shrinkage and fattening of the thymus) is one of the core reasons the immune system weakens and misbehaves with age. It mainly reduces new T-cell production, narrows T-cell diversity, and alters tolerance. [\[242\]](#) [\[243\]](#) [\[244\]](#) [\[245\]](#) [\[246\]](#) [\[247\]](#)

1. Loss of naïve T cells and diversity

- The thymus is where new, **naïve** T cells are made and educated; as it involutes from early adulthood onward, output of new naïve CD4 and CD8 T cells steadily falls. [\[243\]](#) [\[244\]](#) [\[246\]](#) [\[248\]](#)
- With fewer fresh T cells entering the pool, the body relies on expansion of existing clones, leading to a narrower T-cell receptor (TCR) repertoire and poorer ability to recognize new infections and tumor antigens. [\[245\]](#) [\[249\]](#) [\[250\]](#) [\[242\]](#)

2. Immunosenescence: weak responses, poor vaccines

- Reduced naïve T-cell output and skewing toward old, repeatedly stimulated memory/effector T cells underlie **immunosenescence**: weaker responses to new pathogens and vaccines, and slower clearance of infections. [\[244\]](#) [\[250\]](#) [\[251\]](#) [\[242\]](#) [\[243\]](#)
- Clinically, older adults show higher rates of severe infections and lower vaccine efficacy, which correlate with diminished thymic function and reduced T-cell diversity. [\[246\]](#) [\[251\]](#) [\[243\]](#) [\[245\]](#)

3. Inflammaging and autoimmunity

- As thymic function declines, central tolerance (deletion of autoreactive T cells) becomes less efficient, allowing more self-reactive T cells to escape to the periphery. [\[252\]](#) [\[242\]](#) [\[243\]](#) [\[245\]](#)
- These changes contribute to **inflammaging**—chronic, low-grade T-cell-driven inflammation—and higher rates of autoimmune phenomena in older people. [\[253\]](#) [\[247\]](#) [\[254\]](#) [\[242\]](#)

4. Reduced tumor immunosurveillance

- Thymic involution impairs generation of fresh T cells capable of recognizing novel tumor neoantigens, which weakens **tumor immunosurveillance** and contributes to rising cancer incidence with age. [\[255\]](#) [\[243\]](#) [\[245\]](#) [\[253\]](#)
- Modeling and clinical data link thymic decline to increased risk and poorer control of malignancies, as the immune system becomes less able to detect and eliminate emerging cancer cells. [\[248\]](#) [\[242\]](#) [\[255\]](#) [\[245\]](#)

In short, thymic involution is a central driver of age-related immune aging: it quietly shifts the system from flexible, diverse, and balanced toward narrower, inflamed, and less protective. [\[247\]](#) [\[254\]](#) [\[242\]](#) [\[243\]](#) [\[245\]](#)

✱

how does hGH decline due to aging affect the thymus and would increasing hGH help to rejuvenate the thymus

Growth hormone (hGH) decline with age is one factor that contributes to thymic shrinkage and weaker T-cell production, and raising GH/IGF-1 can partially rejuvenate the thymus in animals and in certain human disease settings—but it is not a simple or risk-free anti-aging fix. [\[257\]](#) [\[258\]](#) [\[259\]](#) [\[260\]](#) [\[261\]](#) [\[262\]](#)

How age-related hGH decline affects the thymus

- GH and its mediator IGF-1 are produced in and around the thymus and support thymic epithelial cells (TECs), thymocyte survival, and thymic progenitor entry; GH levels fall with age in parallel with thymic involution and reduced thymopoiesis. [\[258\]](#) [\[259\]](#) [\[260\]](#) [\[262\]](#) [\[257\]](#)
- Experimental and human data suggest that lower GH/IGF-1 signaling with age is one of several factors (along with sex steroids, FOXP1 decline, cytokine changes) that contribute to thymic atrophy and decreased output of naïve T cells. [\[263\]](#) [\[264\]](#) [\[265\]](#) [\[262\]](#) [\[257\]](#)

Does increasing hGH rejuvenate the thymus?

Evidence in animals and in specific human contexts says “partially yes,” but with important caveats:

- In aged mice, GH or IGF-1 administration increases thymic mass, restores TEC architecture, boosts early thymic progenitors, and increases export of naïve T cells with more diverse

T-cell receptors. [\[259\]](#) [\[266\]](#) [\[262\]](#) [\[257\]](#) [\[258\]](#)

- In adults with severe T-cell depletion (notably HIV), recombinant GH has increased thymic size and naïve CD4 T-cell numbers, consistent with improved thymopoiesis. [\[261\]](#) [\[259\]](#)
- A small human pilot (“TRIIM”) using GH plus other agents reported MRI evidence of thymic fat being replaced by denser tissue and improvements in immune aging markers, though the study was tiny and exploratory. [\[267\]](#) [\[268\]](#)

Why it is not a general anti-aging prescription

- GH/IGF-1 are growth-promoting; chronically high levels in adults are linked in other data sets to increased risks of insulin resistance, edema, joint pain, possible neoplasia, and are a concern in people at risk for cancer. [\[264\]](#) [\[260\]](#) [\[262\]](#)
- Reviews emphasize that thymic involution is multifactorial; GH can help, but sex steroids, local thymic factors (FOXP1, FGF/KGF, WNT), and systemic inflammation also need to be considered, and indiscriminate GH replacement in otherwise healthy older adults is not established as safe or beneficial. [\[265\]](#) [\[262\]](#) [\[263\]](#) [\[264\]](#)

So, physiologically, declining hGH contributes to thymic aging, and pharmacologic GH/IGF-1 can rejuvenate thymic structure and output in some settings, but using hGH broadly for “thymus rejuvenation” in normal aging remains experimental and should only be considered in a supervised research or clear medical-need context. [\[260\]](#) [\[257\]](#) [\[258\]](#) [\[259\]](#) [\[267\]](#) [\[261\]](#)

*~

If normal hGH production for a 25 year old considered a risk factor

Normal hGH output for a healthy 25-year-old is **not** considered a cancer risk factor; problems show up mainly when GH/IGF-1 are chronically **above** the normal range (as in acromegaly or overt over-replacement), not when they are physiologic. [\[272\]](#) [\[273\]](#) [\[274\]](#) [\[275\]](#) [\[276\]](#)

GH/IGF-1 and cancer: where the risk is seen

- People with **acromegaly** (pathologically high GH and IGF-1 for many years) have higher rates of several cancers, and cancer risk tracks with the **degree and duration of IGF-1 excess**. [\[277\]](#) [\[273\]](#) [\[274\]](#) [\[275\]](#) [\[278\]](#)
- Epidemiology also links **higher-than-normal IGF-1** to increased risk of some cancers (breast, prostate, colorectal), while both very low and very high IGF-1 associate with worse overall health and mortality. [\[273\]](#) [\[279\]](#) [\[280\]](#) [\[276\]](#)

Normal 25-year-old GH levels

- In contrast, studies of GH replacement in people who are GH-deficient show **no clear increase** in de novo cancer when IGF-1 is kept within the age-adjusted normal range, and some analyses even show lower cancer risk compared with untreated GH-deficient adults. [\[281\]](#) [\[282\]](#) [\[283\]](#) [\[274\]](#)

- Current endocrine guidance generally aims for IGF-1 in the **low-to-mid/upper-normal range**; risk becomes a concern when therapy or disease pushes IGF-1 persistently above the upper normal limit, not when levels are simply “youthful normal.” [\[283\]](#) [\[280\]](#) [\[281\]](#)

So, physiologic hGH production at a 25-year-old’s normal level is not, by itself, considered a cancer risk factor; the concern is **chronic excess** or pharmacologic dosing that drives IGF-1 beyond the normal range for your age. [\[274\]](#) [\[275\]](#) [\[276\]](#) [\[272\]](#) [\[273\]](#)



BPC 157 and TB4 effect on inflammation

Both BPC-157 and thymosin beta-4 (TB-4/TB-500) show anti-inflammatory effects in animal and cell models, but they do it in somewhat different ways and all data are still preclinical or very early-stage. [\[287\]](#) [\[288\]](#) [\[289\]](#) [\[290\]](#) [\[291\]](#)

BPC-157 and inflammation

- BPC-157 reduces pro-inflammatory signaling at injury sites, with reports of down-modulating cytokines (like TNF- α , IL-1 β) and limiting neutrophil and macrophage-driven tissue damage in gut, muscle, and vascular injury models. [\[288\]](#) [\[289\]](#) [\[292\]](#) [\[293\]](#)
- It also improves endothelial function via VEGFR2–Akt–eNOS and nitric oxide, which can stabilize the vascular barrier and reduce edema and inflammatory leakage. [\[294\]](#) [\[295\]](#) [\[296\]](#) [\[287\]](#)
- Functionally, models show less swelling, less scar formation, and faster resolution of acute inflammation, but long-term effects on systemic inflammation in healthy humans are unknown. [\[289\]](#) [\[292\]](#) [\[287\]](#) [\[288\]](#)

Thymosin beta-4 (TB-4 / TB-500) and inflammation

- TB-4 is best known for actin and cell-migration effects but also modulates inflammation: it can reduce NF- κ B activation, decrease certain pro-inflammatory cytokines, and promote resolution in cardiac, corneal, and skin injury models. [\[290\]](#) [\[291\]](#) [\[297\]](#)
- It supports endothelial repair and angiogenesis, which indirectly dampens chronic inflammatory signaling by restoring normal tissue and microvascular structure. [\[291\]](#) [\[287\]](#) [\[290\]](#)

Combined use (BPC-157 + TB-4)

- When combined, they appear to reduce local inflammatory signaling more than either alone while improving vascular repair and NO signaling; this is described as “inflammation control” that supports higher-quality healing in preclinical and anecdotal clinical reports. [\[287\]](#) [\[290\]](#) [\[291\]](#)
- However, robust human trials quantifying CRP, IL-6, or other systemic markers under these peptides are lacking, so their effect on whole-body inflammation and long-term risk (including cancer) remains uncertain. [\[292\]](#) [\[288\]](#) [\[289\]](#) [\[290\]](#) [\[291\]](#)

If you tell me whether you're thinking about joint pain, gut inflammation, or systemic markers (CRP, IL-6), I can map what current evidence does and doesn't support for that specific use.

*
**

1. https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor
2. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3411125/>
3. <https://pmc.ncbi.nlm.nih.gov/articles/PMC551528/>
4. <https://www.sigmaaldrich.com/CA/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/mammalian-cell-culture/vascular-endothelial>
5. <https://www.news-medical.net/life-sciences/VEGF-Classification.aspx>
6. <https://www.sciencedirect.com/science/article/pii/S0014579306004157>
7. <https://www.yeasenbio.com/blogs/cell/how-to-choose-vegf-family-protein-correctly>
8. <https://www.nature.com/articles/s41392-025-02249-0>
9. <https://www.nature.com/articles/1201090>
10. <https://pubmed.ncbi.nlm.nih.gov/11312110/>
11. <https://www.sciencedirect.com/science/article/abs/pii/S1357272501000279>
12. <https://www.creative-diagnostics.com/vegf-family.htm>
13. <https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=324>
14. <https://pmc.ncbi.nlm.nih.gov/articles/PMC551528/>
15. https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor
16. <https://www.bio-techno.com/reagents/proteins/growth-factors/vegf-family>
17. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3405829/>
18. <https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/mammalian-cell-culture/vascular-endothelial>
19. <https://www.creative-diagnostics.com/vegf-family.htm>
20. <https://www.news-medical.net/life-sciences/Vascular-Endothelial-Growth-Factor.aspx>
21. <https://www.ncbi.nlm.nih.gov/books/NBK6149/>
22. <https://www.betalifesci.com/pages/vegf-family-vegfs-and-receptors>
23. <https://www.nature.com/articles/s41392-025-02249-0>
24. <https://www.sciencedirect.com/science/article/pii/S0014299923000973>
25. <https://www.ncbi.nlm.nih.gov/books/NBK6482/>
26. <https://ashpublications.org/blood/article/109/3/1010/23861/VEGF-C-induced-lymphangiogenesis-in-sentinel-lymph>
27. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10274152/>
28. <https://ascopubs.org/doi/10.1200/JCO.2005.06.081>
29. <https://pubmed.ncbi.nlm.nih.gov/12566318/>
30. <https://aacrjournals.org/clincancerres/article/15/11/3648/73627/Antimyeloidangiogenic-Therapy-for-Cancer-by>
31. <https://www.nature.com/articles/onc20174>

32. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4011842/>
33. <https://www.embopress.org/doi/full/10.1093/emboj/20.4.672>
34. <https://www.sciencedirect.com/science/article/pii/S0893395222050244>
35. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2752403/>
36. <https://www.pnas.org/doi/10.1073/pnas.1309629110>
37. <https://www.nature.com/articles/s41392-025-02249-0>
38. <https://www.sciencedirect.com/science/article/abs/pii/S1043466625000559>
39. https://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor
40. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8265599/>
41. <https://www.rndsystems.com/resources/articles/vascular-endothelial-growth-factor-vegf>
42. <https://www.sciencedirect.com/topics/neuroscience/vascular-endothelial-growth-factor>
43. <https://www.molbiolcell.org/doi/10.1091/mbc.e09-07-0591>
44. <https://www.ncbi.nlm.nih.gov/books/NBK6149/>
45. <https://academic.oup.com/edrv/article/25/4/581/2355249>
46. <https://www.urmc.rochester.edu/encyclopedia/content?ContentTypeID=167&ContentID=vegf>
47. <https://www.ncbi.nlm.nih.gov/books/NBK6482/>
48. <https://www.nature.com/articles/s41392-025-02249-0>
49. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/>
50. <https://pubmed.ncbi.nlm.nih.gov/27847966/>
51. <https://www.nature.com/articles/s41598-020-74022-y>
52. https://www.nutrahacker.com/journal_club/en/TB500.php
53. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/>
54. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/>
55. <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.767785/full>
56. https://www.benchchem.com/pdf/BPC_157_and_its_interaction_with_the_VEGFR2_Akt_eNOS_pathway.pdf
57. <http://www.gicancer.or.kr/content/event/pdf/iasgo/day3/06.pdf>
58. <https://pubmed.ncbi.nlm.nih.gov/20388964/>
59. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/>
60. <https://swolverine.com/blogs/blog/bpc-157-side-effects-and-safety-what-you-need-to-know-before-starting>
61. <https://www.ncbi.nlm.nih.gov/books/NBK6482/>
62. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10274152/>
63. <https://ascopubs.org/doi/10.1200/JCO.2005.06.081>
64. <https://peptpedia.org/research/bpc-157-angiogenesis>
65. <https://www.peptidesciences.com/peptide-research/thymosin-beta-4-neuropathy-senescence>
66. <https://ospinamedical.com/orthopedic-blog/peptide-therapy-101-can-bpc-157-thymosin-beta-4-accelerate-ortho-recovery>
67. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/>

68. <https://www.droracle.ai/articles/234798/is-tb-500-thymosin-beta-4-peptide-safe-and-effective-for>
69. <https://www.cochrane-handbook.org/bpc-157-and-cancer-understanding-the-research-and-risks/>
70. <https://www.droracle.ai/articles/590734/what-are-the-adverse-effects-of-tb-500-thymosin>
71. <https://oathpeptides.com/2025/11/01/is-bpc-157-fda-approved-current-status/>
72. <https://swolverine.com/en-ca/blogs/blog/tb-500-side-effects-safety-for-men-women-what-the-latest-studies-show>
73. <https://ziba.guru/2025/04/first-human-trial-of-intravenous-bpc-157-begins-amid-fda-warnings-and-wada-scrutiny/>
74. <https://ziba.guru/2025/04/bpc-157-in-humans-first-pilot-study-shows-safety-and-tolerability-but-clinical-trials-are-needed/>
75. <https://www.innerbody.com/thymosin-beta-4-and-tb-500>
76. <https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger>
77. <https://www.cochrane-handbook.org/bpc-157-and-cancer-risk-separating-fact-from-fiction/>
78. <https://pubmed.ncbi.nlm.nih.gov/27847966/>
79. https://www.benchchem.com/pdf/BPC_157_and_its_interaction_with_the_VEGFR2_Akt_eNOS_pathway.pdf
80. <https://pubmed.ncbi.nlm.nih.gov/29898649/>
81. <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.767785/full>
82. <https://www.ncbi.nlm.nih.gov/books/NBK6482/>
83. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10274152/>
84. <https://ascopubs.org/doi/10.1200/JCO.2005.06.081>
85. <https://journals.library.columbia.edu/index.php/cusj/blog/view/720>
86. <https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/>
87. <https://medisearch.io/blog/bpc157-and-cancer-risk>
88. <https://www.proteinatlas.org/ENSG00000112715-VEGFA/tissue>
89. <https://www.pnas.org/doi/10.1073/pnas.0906670106>
90. <https://www.molbiolcell.org/doi/10.1091/mbc.e09-07-0591>
91. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2814783/>
92. <https://www.pnas.org/doi/10.1073/pnas.95.26.15809>
93. <https://pmc.ncbi.nlm.nih.gov/articles/PMC19570/>
94. https://minuth.app.uni-regensburg.de/PDF/Proceedings/2013_Klettner.pdf
95. <https://pubmed.ncbi.nlm.nih.gov/40032151/>
96. <https://www.sciencedirect.com/science/article/abs/pii/S0014483525000892>
97. <https://pubmed.ncbi.nlm.nih.gov/7641334/>
98. <https://academic.oup.com/edrv/article/25/4/581/2355249>
99. <https://www.ncbi.nlm.nih.gov/books/NBK6482/>
100. <https://www.nature.com/articles/s41392-025-02249-0>
101. <https://www.sciencedirect.com/science/article/pii/S0092867419300546>
102. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1850188/>

103. <https://pubmed.ncbi.nlm.nih.gov/27847966/>
104. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4286745/>
105. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/>
106. <https://pubmed.ncbi.nlm.nih.gov/20691219/>
107. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/>
108. <https://en.wikipedia.org/wiki/BPC-157>
109. <http://www.gicancer.or.kr/content/event/pdf/iasgo/day3/06.pdf>
110. <https://pubmed.ncbi.nlm.nih.gov/20388964/>
111. https://jpp.krakow.pl/journal/archive/12_09_s7/pdf/191_12_09_s7_article.pdf
112. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8751378/>
113. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/>
114. <https://rps.researchcommons.org/cgi/viewcontent.cgi?article=1418&context=journal>
115. <https://peptpedia.org/research/bpc-157-angiogenesis>
116. <https://homedoc.com.au/blog/bpc-157-the-peptide-that-promises-healingbut-should-you-actually->
117. <https://www.sciencedirect.com/science/article/pii/S1016847823053153>
118. <https://pubmed.ncbi.nlm.nih.gov/27847966/>
119. <https://www.nature.com/articles/s41598-020-74022-y>
120. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4286745/>
121. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4182666/>
122. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/>
123. <https://www.sciencedirect.com/science/article/pii/S0167488910001990>
124. <https://swolverine.com/en-ca/blogs/blog/tb500-vs-bpc-157-unveiling-the-ultimate-healing-peptides-for-recovery-and-performance>
125. <https://pubmed.ncbi.nlm.nih.gov/20691219/>
126. https://www.benchchem.com/pdf/BPC_157_and_its_interaction_with_the_VEGFR2_Akt_eNOS_pathway.pdf
127. https://www.benchchem.com/pdf/BPC_157_A_Technical_Guide_to_its_Mechanism_of_Action_in_Tissue_Regeneration.pdf
128. <https://en.wikipedia.org/wiki/BPC-157>
129. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/>
130. <https://pubmed.ncbi.nlm.nih.gov/20388964/>
131. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8751378/>
132. <https://resources.mobilecarehealth.com/thymosin-bpc/>
133. <https://hub.tmu.edu.tw/en/publications/therapeutic-potential-of-pro-angiogenic-bpc157-is-associated-with>
134. <https://thegajerpractice.com/blog/healing-from-the-inside-out-how-bpc-157-and-thymosin-beta-4-support-deep-repair/>
135. <https://hub.tmu.edu.tw/en/publications/therapeutic-potential-of-pro-angiogenic-bpc157-is-associated-with/>
136. <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0106532>

137. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4354930/>
138. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5913290/>
139. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5614326/>
140. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7791626/>
141. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329223/>
142. <https://www.bbc.com/future/article/20240209-how-cancer-risk-increases-with-age>
143. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5988260/>
144. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4509784/>
145. <https://www.sciencedirect.com/science/article/pii/S1550413122004922>
146. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10531692/>
147. <https://pubmed.ncbi.nlm.nih.gov/36599298/>
148. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12374445/>
149. <https://www.nature.com/articles/s41598-025-20084-9>
150. <https://www.sciencedirect.com/science/article/pii/S246850111730010X>
151. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9134968/>
152. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9844150/>
153. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12711513/>
154. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4425163/>
155. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9490147/>
156. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4354930/>
157. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5913290/>
158. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5614326/>
159. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329223/>
160. <https://www.aging-us.com/article/203656/pdf>
161. <https://pubmed.ncbi.nlm.nih.gov/34102225/>
162. <https://academic.oup.com/jnci/article/113/2/112/5827003>
163. <https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/how-diet-and-physical-activity-impact-cancer-risk/anti-inflammatory-diets-and-cancer.html>
164. <https://www.aicr.org/resources/blog/can-an-anti-inflammatory-diet-reduce-cancer-risk/>
165. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4058555/>
166. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1708280/full>
167. <https://www.sciencedirect.com/science/article/pii/S1550413122004922>
168. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7791626/>
169. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10531692/>
170. <https://pubmed.ncbi.nlm.nih.gov/41425546/?fc=None&ff=20251223155720&v=2.18.0.post22+67771e2>
171. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4509784/>
172. <https://www.bbc.com/future/article/20240209-how-cancer-risk-increases-with-age>
173. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8361780/>
174. <https://www.sciencedirect.com/science/article/pii/S0014482721002111>

175. <https://ecancer.org/en/news/22838-researchers-discover-a-way-to-fight-the-aging-process-and-cancer-development>
176. <https://pmc.ncbi.nlm.nih.gov/articles/PMC1857231/>
177. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5351698/>
178. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6422365/>
179. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10681516/>
180. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11892258/>
181. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7653700/>
182. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2014.00197/full>
183. <https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1643024/full>
184. <https://www.jci.org/articles/view/31405>
185. <https://www.nature.com/articles/s41568-025-00858-z>
186. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12374445/>
187. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5614326/>
188. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4354930/>
189. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329223/>
190. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12711513/>
191. <https://pubmed.ncbi.nlm.nih.gov/41425546/?fc=None&ff=20251223155720&v=2.18.0.post22+67771e2>
192. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1708280/full>
193. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6169832/>
194. <https://elifesciences.org/articles/04476>
195. <https://www.sciencedirect.com/science/article/abs/pii/S1040842801001688>
196. <https://www.cancerresearch.org/blog/the-impact-of-immune-monitoring-for-the-early-detection-of-cancer>
197. <https://www.ncbi.nlm.nih.gov/books/NBK604207/>
198. <https://medlineplus.gov/lab-tests/complete-blood-count-cbc/>
199. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12123219/>
200. <https://www.ncbi.nlm.nih.gov/books/NBK230966/>
201. <https://www.sciencedirect.com/science/article/pii/S0531556524000755>
202. <https://www.mayoclinic.org/tests-procedures/complete-blood-count/about/pac-20384919>
203. <https://my.clevelandclinic.org/health/body/23342-lymphocytes>
204. <https://www.cancercenter.com/community/blog/2023/05/when-to-worry-about-low-lymphocytes>
205. <https://www.hopkinslupus.org/lupus-tests/screening-laboratory-tests/complete-blood-count-cbc/>
206. <https://pubmed.ncbi.nlm.nih.gov/16214925/>
207. <https://www.cancer.org/cancer/risk-prevention/diet-physical-activity/how-diet-and-physical-activity-impact-cancer-risk/anti-inflammatory-diets-and-cancer.html>
208. <https://www.aicr.org/resources/blog/can-an-anti-inflammatory-diet-reduce-cancer-risk/>
209. <https://pubmed.ncbi.nlm.nih.gov/41425546/?fc=None&ff=20251223155720&v=2.18.0.post22+67771e2>
210. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8393680/>

211. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10603340/>
212. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8125302/>
213. <https://www.nature.com/articles/s41392-023-01451-2>
214. <https://informedix.com/lab-panels/cbc-with-differential/>
215. <https://pmc.ncbi.nlm.nih.gov/articles/PMC440627/>
216. https://en.wikipedia.org/wiki/CD4+/CD8+_ratio
217. <https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.10011>
218. <https://www.webmd.com/hiv-aids/what-to-know-about-cd4-cd8-ratio-test>
219. https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=167&contentid=cd4_cd8_ratio
220. <https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.b.10011>
221. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5667733/>
222. <https://www.verywellhealth.com/how-important-is-your-cd4-cd8-ratio-48781>
223. <https://i-base.info/qa/20>
224. <https://www.aidsmap.com/about-hiv/cd4cd8-ratio>
225. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4785819/>
226. <https://www.fightaging.org/archives/2021/06/cd4-cd8-t-cell-ratio-as-a-measure-of-immune-aging/>
227. https://en.wikipedia.org/wiki/CD4+/CD8+_ratio
228. <https://pubmed.ncbi.nlm.nih.gov/26051633/>
229. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8202849/>
230. <https://pmc.ncbi.nlm.nih.gov/articles/PMC440627/>
231. <https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.10011>
232. <https://pubmed.ncbi.nlm.nih.gov/36136908/>
233. <https://www.sciencedirect.com/science/article/pii/S1279770723005389>
234. <https://www.aidsmap.com/about-hiv/cd4cd8-ratio>
235. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11004734/>
236. <https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2022/cd4-cd8>
237. https://natap.org/2013/HIV/091113_01.htm
238. <https://www.eatg.org/hiv-news/cd4cd8-ratio-recovery-slows-among-people-starting-antiretroviral-treatment-after-age-60-reports-uk-based-study/>
239. <https://www.aging-us.com/article/203109/text>
240. <https://pubmed.ncbi.nlm.nih.gov/35013081/>
241. <https://www.science.org/doi/10.1126/sciimmunol.adv7615>
242. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6971920/>
243. <https://pubmed.ncbi.nlm.nih.gov/35822239/>
244. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2750859/>
245. <https://www.longdom.org/open-access/thymic-involution-and-its-effects-on-t-cell-repertoire-1104259.html>
246. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00316/full>

247. <https://www.fightaging.org/archives/2020/02/thymic-involution-contributes-to-immunosenescence-and-inflammaging/>

248. <https://pubmed.ncbi.nlm.nih.gov/40067592/>

249. <https://www.pnas.org/doi/10.1073/pnas.1409155111>

250. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4096164/>

251. <https://www.sciencedirect.com/science/article/abs/pii/S1044532323001288>

252. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4673115/>

253. <https://pubmed.ncbi.nlm.nih.gov/31988649/>

254. <https://pubmed.ncbi.nlm.nih.gov/39042204/>

255. <https://www.pnas.org/doi/10.1073/pnas.1714478115>

256. <https://onlinelibrary.wiley.com/doi/abs/10.1111/accel.13671>

257. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2914845/>

258. <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1108630/full>

259. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2682582/>

260. <https://pubmed.ncbi.nlm.nih.gov/20434952/>

261. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2248805/>

262. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2924688/>

263. <https://www.sciencedirect.com/science/article/abs/pii/S1521661605002925>

264. <https://pubmed.ncbi.nlm.nih.gov/37659170/>

265. <https://onlinelibrary.wiley.com/doi/10.1111/accel.13671>

266. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2556619/>

267. https://www.natap.org/2019/HIV/092519_02.htm

268. <https://www.lifespan.io/road-maps/the-rejuvenation-roadmap/intervene-immune-hgh-dhea>

269. <https://pubmed.ncbi.nlm.nih.gov/26169108/>

270. <https://pubmed.ncbi.nlm.nih.gov/35822239/>

271. <https://pubmed.ncbi.nlm.nih.gov/22261974/>

272. <https://www.tga.gov.au/news/blog/too-much-good-thing-health-risks-human-growth-hormone>

273. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6603614/>

274. <https://academic.oup.com/jcem/article/102/5/1661/2982840>

275. <https://pubmed.ncbi.nlm.nih.gov/38986012/>

276. <https://academic.oup.com/edrv/article/40/2/558/5214057>

277. <https://www.endocrinologyadvisor.com/news/igf-1-levels-predict-cancer-risk/>

278. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12168067/>

279. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4258605/>

280. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8844108/>

281. <https://www.sciencedirect.com/science/article/abs/pii/S1521690X2300091X>

282. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5348436/>

283. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11900236/>

284. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6061931/>

285. <https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/natour-press-release>
286. <https://www.oncologynurseadvisor.com/news/igf-1-levels-predict-cancer-risk/>
287. [what-are-the-synergies-between-zNUin5TIRjCz_0izjvNEng.md](#)
288. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/>
289. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12567428/>
290. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/>
291. <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.767785/full>
292. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/>
293. <https://pubmed.ncbi.nlm.nih.gov/20388964/>
294. <https://pubmed.ncbi.nlm.nih.gov/27847966/>
295. <https://www.nature.com/articles/s41598-020-74022-y>
296. https://www.benchchem.com/pdf/BPC_157_and_its_interaction_with_the_VEGFR2_Akt_eNOS_pathway.pdf
297. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8751378/>